Mentixa

Memantine hydrochloride, the active ingredient in Mentixa, is a NMDA receptor antagonist presented as an oral tablet for oral use. It is indicated for the treatment of Alzheimer’s disease in adults and helps to reduce excitotoxic neuronal damage. GNH USA supplies Mentixa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Memantine hydrochloride is used in the management of neurodegenerative disorders that involve glutamatergic excitotoxicity. - Alzheimer's disease: improves cognition and functional abilities in patients with mild to moderate disease.

Adverse reactions to memantine are reported across a range of frequencies.

Common Side Effects: - Dizziness: transient light‑headedness, especially at treatment initiation. - Headache: mild to moderate intensity, often resolves with continued therapy. - Constipation: reduced bowel movements, manageable with diet. - Confusion: occasional disorientation, more common in elderly.

Serious or Rare Side Effects: - Seizures: rare but may occur, particularly in patients with a seizure history. - Allergic reactions: rash, pruritus, or angioedema requiring medical attention. - Hallucinations or psychosis: uncommon neuropsychiatric events. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis, extremely rare.

Memantine should be used with attention to patient‑specific factors and storage conditions. - Renal impairment: dose adjustment may be required in patients with reduced kidney function. - History of seizures: monitor closely for increased seizure activity. - Concomitant NMDA antagonists: avoid combined use to prevent additive CNS effects. - Pregnancy: safety not established; use only if potential benefit justifies the risk. - Elderly patients: monitor for confusion or worsening cognition. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Memantine may interact with other medicines that affect the central nervous system or NMDA pathways.

Major Interactions (Avoid): - Amantadine: additive NMDA antagonism may increase neurotoxicity. - Ketamine: combined CNS depression and potential for severe confusion. - Other NMDA antagonists: risk of excessive blockade leading to adverse neurologic effects.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: may exacerbate confusion or cognitive decline. - Diuretics: possible alterations in blood pressure and electrolyte balance. - CNS depressants (e.g., benzodiazepines): may increase dizziness and sedation.